Valuation: ALLOVIRPAR

Market Cap 49.21M 42.57M 39.75M 36.47M 68.59M 4.68B 69.68M 466M 183M 2.35B 185M 181M 7.76B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -59.75M -55.8M -51.19M -96.28M -6.57B -97.81M -655M -257M -3.3B -259M -254M -10.89B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-1.11%
Current month-59.28%
Current year-59.28%
3 years 3.97
Extreme 3.97
86.25
5 years 3.97
Extreme 3.97
607.43
10 years 3.97
Extreme 3.97
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -165M -154M -141M -265M -18.12B -270M -1.8B -708M -9.08B -715M -699M -30.03B -58.77M -50.84M -47.47M -43.55M -81.91M -5.59B -83.21M -557M -219M -2.8B -221M -216M -9.27B
Net Debt -157M -135M -126M -116M -218M -14.9B -222M -1.48B -582M -7.47B -588M -575M -24.68B -118M -102M -95.55M -87.65M -165M -11.26B -167M -1.12B -440M -5.64B -444M -434M -18.65B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
11/08/26 USD 3.995 -1.84% 8,165
07/08/26 USD 4.070 -2.86% 58,833
06/08/26 USD 4.190 0.00% 55,619
05/08/26 USD 4.190 -3.01% 26,402
04/08/26 USD 4.320 +6.67% 133,653
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock